SEC filing record
Primary Source · SEC.gov

Cambrian BioPharma Inc

2026 vintageRule 506(c)Filing record

Built from the SEC filing index the day the filing landed. The figures below are the issuer's own from Form D; AltStreet's analysis, sponsor link and data flags follow when the entity is enriched.

Latest signalNew Form D filerForm D · 2026-07-155 events: 1 new form d filer, 1 large raise, 1 offering downsizedLast filing 2026-07-15

Raised

$124M

Investors

80

Min Invest

None stated

AltStreet Verified Issuer badge

Is this your company or fund? Claim this page free, or verify it and carry the Verified Issuer mark.

What this filing shows

·

Every sentence is a value as filed on SEC Form D

Cambrian BioPharma Inc is a Delaware corporation that first filed a Form D on January 27, 2020 and most recently amended it on July 15, 2026 in the Biotechnology industry group. The offering claims Rule 506(c) and covers equity. Cambrian BioPharma Inc reported $123,751,064 sold from 80 investors of a $129,751,064 total offering as of the Form D filed July 15, 2026. The offering relies on Rule 506(c), so the issuer may advertise it but may sell only to investors it has verified as accredited. The filing reports no non-accredited investors. The filing lists the minimum investment as $0, meaning no minimum was stated. The Form D names no recipient of sales compensation, which usually means the issuer or its affiliates are placing the securities directly. The issuer's address of record is 228 Park Avenue S., #66643, New York, NY 10003.

EDGAR Filing Data

Form D — Primary Source

View on SEC.gov
CIK Number0001797409
Entity NameCambrian BioPharma Inc
ExemptionRule 506(c)
What the exemption meansRule 506(c) of Regulation D: the issuer may advertise the offering publicly, but every purchaser must be a verified accredited investor.
Entity TypeCorporation
Jurisdiction of OrganizationDelaware
Issuer Address228 Park Avenue S., #66643, New York, NY 10003
Phone(516) 962-3186
Industry / Fund TypeBiotechnology
Securities TypeEquity
First Sale DateJune 30, 2026
Filing DateJuly 15, 2026
Accession Number0000950172-26-000183
Total Offering Amount$129,751,064
Total Amount Sold$123,751,064
Amount Remaining$6,000,000
Total Investors80
Non-Accredited InvestorsNone
Minimum Investment$0 (no stated minimum)
Offering DurationOne year or less
Revenue RangeDecline to Disclose
State (Issuer Address)NY
Amendment Count6 filings on record

Filings on Record

Every filing AltStreet's ledger holds for this CIK, newest first. Each opens the SEC archive folder.

In the Terminal

Filing events

5

latest Jul 15, 2026

Critical / warning

0 / 1

4 watch · 0 info

Statements extracted

0

none on file

NAV prints

0

none on file

Offering chains

5

closed, lapsed, dark, raising

Latest event New filer · Jul 15, 2026

SEC.gov
Open in the terminal Watch this issuerInvestor $149/mo unlocks the values; Pro $349/mo adds the universe.

Investor

  • 5 filing events with values and deltas, latest 2026-07-15, and alerts on the next one
  • 5 offering timelines: velocity, share raised, first-sale lag, stalled flags

Pro

  • This issuer against its cohort: rank by velocity and share raised among offerings filed the same quarter
  • The same events, statements and NAV moves across every issuer, screenable, with unlimited watches and CSV

Counts and dates above are the free record. The values, the series and the comparisons are the seat. Loading your view…

Related Persons (Form D)

Executive officers, directors, and promoters listed on the SEC Form D filing. Source: SEC.gov.

Item 3 changed on the Form D filed 2026-07-15: 7 related persons added and 1 removed against the filing of 2025-01-13; 11 now listed. The names are in the Terminal feed.

James Peyer

Executive Officer, Director · New York, NY

Juliette Han

Executive Officer, Director · New York, NY

Mark Nuttall

Executive Officer · New York, NY

Ruth Thieroff-Ekerdt

Executive Officer · New York, NY

William DeVaul

Executive Officer · New York, NY

Christian Angermeyer

Director · Birkirkara, O1

Maryanna Saenko

Director · Los Altos, CA

Brenton L. Saunders

Director · Bridgewater, NJ

Paul Farr

Director · Santa Monica, CA

Martin Gunhaga

Director · Umea, V7

Lorin Van Nuland

Director · Birkirkara, O1

Questions About Cambrian BioPharma Inc

Each answer is built from the values on the SEC filing and the AltStreet ledger, not from the issuer's marketing.

What is Cambrian BioPharma Inc?

Cambrian BioPharma Inc is a Delaware corporation that filed a Form D with the SEC on July 15, 2026 in the Biotechnology industry group. The filing claims Rule 506(c) for an offering of equity.

Is Cambrian BioPharma Inc legit?

AltStreet does not rate legitimacy; it reports the public record. Cambrian BioPharma Inc filed a Form D with the SEC on July 15, 2026 claiming Rule 506(c). A Form D is a notice of an exempt offering, not a review or approval of it. The newest notice reports $123,751,064 sold to 80 investors. AltStreet's enforcement record (SEC, FINRA and state actions) shows no action naming the issuer as of today. Before investing, confirm the filing on EDGAR, check the seller's registration on FINRA BrokerCheck, and read the offering documents, which a Form D does not include.

Is Cambrian BioPharma Inc registered with or approved by the SEC?

No. A Form D is a notice that an issuer is selling securities under an exemption from registration, and the SEC does not review, approve, or pass on the merits of the offering. The filing shows that Cambrian BioPharma Inc claimed Rule 506(c) and disclosed the items the form requires, such as the amount sold, the minimum investment, related persons, and anyone paid to sell the securities. It does not verify the issuer's claims or its business.

How much has Cambrian BioPharma Inc raised?

Cambrian BioPharma Inc reported $123,751,064 sold from 80 investors of a $129,751,064 total offering as of the Form D filed July 15, 2026.

Who can invest in Cambrian BioPharma Inc?

The offering relies on Rule 506(c), so the issuer may advertise it but may sell only to investors it has verified as accredited. The filing reports no non-accredited investors. The filing lists the minimum investment as $0, meaning no minimum was stated.

What is the minimum investment in Cambrian BioPharma Inc?

The Form D lists the minimum investment as $0, which means the issuer did not state a minimum on the form. The offering documents, not the Form D, set the actual subscription terms.

Who is selling Cambrian BioPharma Inc and how are they paid?

The Form D names no recipient of sales compensation, which usually means the issuer or its affiliates are placing the securities directly.

Who is behind Cambrian BioPharma Inc?

The Form D lists 11 related persons: James Peyer, executive officer, director; Juliette Han, executive officer, director; Mark Nuttall, executive officer; Ruth Thieroff-Ekerdt, executive officer; William DeVaul, executive officer; Christian Angermeyer, director; Maryanna Saenko, director; Brenton L. Saunders, director, and 3 more. Form D Item 3 requires executive officers, directors, and promoters of the issuer to be listed.

Where is Cambrian BioPharma Inc located?

The issuer's address on its SEC filings is 228 Park Avenue S., #66643, New York, NY 10003. Its phone number of record is (516) 962-3186. It is organized under the laws of Delaware.

How long is the Cambrian BioPharma Inc offering open?

The issuer indicated that the offering is not intended to last more than one year. An issuer must amend its Form D annually while a continuing offering stays open; 1 amendment is on record for this CIK.

What is Cambrian BioPharma Inc's revenue?

The issuer declined to disclose its revenue range on the Form D, which the form permits.

AltStreet Verified Issuer badge

Is this your company or fund?

Free claim: add your contact details, website, team and a description to this page. The filed facts stay as filed.

Verified Issuer, $480 a year: AltStreet checks the identity of your company and the authority of the person claiming it against your filings, confirms your contact details on a stated date and again at each renewal, and marks the page so people researching you find a current, attributed profile beside the public filing record. It is not a review of any offering.

Data Methodology

Capital raise figures, investor counts, and filing dates are sourced directly from SEC EDGAR Form D primary documents via the SEC EDGAR submissions API and full-text search index. EDGAR entity profiles and deal-level data are reviewed by AltStreet analysts with backgrounds in corporate finance and securities law — cross-referenced against offering circulars, audited financial statements, and primary regulatory filings before publication. Platform-provided information, where present, is clearly labeled and does not affect EDGAR data or AltStreet editorial coverage. Platforms may request factual corrections for demonstrable inaccuracies by contacting [email protected]. This page does not constitute investment advice.